1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016; 134(6):441-450.
2. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension--United States, 1999-2002 and 2005-2008. MMWR Morbidity and Mortality Weekly Report. 2011; 60(4):103-108.
3. Goldman L, Schafer AI. Goldman’s Cecil Medicine E-Book: Expert Consult Premium Edition--Enhanced Online Features and Print, Single Volume: Elsevier Health Sciences; 2011.
4. Chen W, Gao R, Liu L, Zhu M, Wang W, Wang Y, et al. Report on Cardiovascular Diseases in China (2014). In. Edited by Xiaoqun H. Encyclopedia of China Publishing House: National Center for Cardiovascular Diseases, China; 2015: 182.
5. Wu Y. Research progress on epidemiology of hypertension and its risk factors in Chinese population [in Chinese]. Bull Med R 2003; 32(12):27-29.
6. Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation. 2008; 118(25):2679-2686.
7. Li Y, Wang L, Jiang Y, Li X, Zhang M, Hu N. Prevalence of hypertension among Chinese adults in 2010[in Chinese]. Zhonghua Yufang Yixue Zazhi. 2012; 46(5):409-413.
8. Hu R, Zou H, Shen C, Heng F. Health Care System Reform in China: Issues, Challenges and Options. In. Beijing.China: China Economics and Management Academy, Central University of Finance and Economics; 2011.
9. Communist Party of China Central Committee. Implementation plan for the recent priorities of the health care system reform (2009–2011). In. Volume 38, edn. Beijing: People’s Publishing House, PRC; 2009.
10. Mingji C, Onakpoya IJ, Perera R, Ward AM, Heneghan CJ. Relationship between altitude and the prevalence of hypertension in Tibet: a systematic review. Heart. 2015; 101(13):1054-1060.
11. Tibet Autonomous Region Bureau of Statistics. Tibet Statistical Yearbook 2015 [in Chinese]. Beijing: China Statistics Press; 2015.
12. Pingcuo Zhuoma, Qi Jinlei, Gama Cangjue, Yajie L. Analysis on major death causes and disease burden in residents in Tibet, 2015. Disease Suveillance [in Chinese]. 2019; 30(01):66-69.
13. Zhao X, Li S, Ba S, He F, Li N, Ke L, et al. Prevalence, awareness, treatment, and control of hypertension among herdsmen living at 4,300 m in Tibet. Am J Hypertens. 2012; 25(5):583-589.
14. Wang J, Zhang L, Wang F, Liu L, Wang H. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens. 2014; 27(11):1355-1361.
15. Hu Y, Yao C, Wang W, Hu J, He Y, Zhai F. Survey on the prevalence of hypertension in different ethnic groups in China in 2002 [in Chinese]. Wei Sheng Yan Jiu = J Hyg Res. 2006; 35(5):573-575.
16. Aryal N, Weatherall M, Bhatta YK, Mann S. Blood Pressure and Hypertension in Adults Permanently Living at High Altitude: A Systematic Review and Meta-Analysis. High Alt Med Biol. 2016; 17(3):185-193.
17. Fiori G, Facchini F, Pettener D, Rimondi A, Battistini N, Bedogni G. Relationships between blood pressure, anthropometric characteristics and blood lipids in high-and low-altitude populations from Central Asia. Ann Hum Biol. 2000; 27(1):19-28.
18. China Daily. Development and progress of Tibet. In. http://www.chinadaily.com.cn/kindle/2013-10/23/content_17052580.htm. Beijing: Xinhua News Agency; 2013.
19. Cheng Y. Three million people in Tibet received free physical examinations for seven consecutive years [in Chinese]. In. http://www.xinhuanet.com/local/2018-04/07/c_1122645827.htm. Lhasa: Xin Hua Net; 2018.
20. National Grassroots Hypertension Management Office. 2017 national guidelines for the prevention and management of hypertension at the grassroots level [in Chinese]. In. Bei Jing: National Cardiovasculour Disease Center; 2017.
21. Liu L. 2010 Chinese guidelines for the management of hypertension [in Chinese]. Chin J Hypertens. 2011; 19(7):701-743.
22. Song C, Chongsuvivatwong V, Zhu Luo Bu O, Ji D, Sang Zhuo Ma B, Sriplung H. Relationship between hypertension and geographic altitude: a cross-sectional survey among residents in Tibet. J Int Med Res. 2020 Feb; 48(2):300060520903645.
23. Wikipedia. Tibet Autonomous Region. https://en.wikipedia.org/wiki/Tibet_Autonomous_Region.
24. Zheng X, Yao DK, Zhuo-Ma CR, Tang J, Wang TR, Zhang HH, et al. Prevalence, self-awareness, treatment, and control of hypertension in Lhasa, Tibet. Clinical and experimental hypertension. 2012; 34(5):328-333.
25. Cho K, Tian M, Lan Y, Zhao X, Yan LL. Validation of the Omron HEM-7201 upper arm blood pressure monitor, for self-measurement in a high-altitude environment, according to the European Society of Hypertension International Protocol revision 2010. J Hum Hypertens. 2013; 27(8):487-491.
26. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases--report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. Biomed Environ Sci. 2002; 15(3):245-252.
27. Schmidt BM, Durão S, Toews I, Bavuma CM, Meerpohl JJ, Kredo T. Screening strategies for hypertension: a systematic review protocol. BMJ Open. 2019; 9(1):e025043.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-2571.
29. Shengelia B, Ajay T, Adams OB, Murray CJL. Access, utilization, quality, and effective coverage: an integrated conceptual framework and measurement strategy. Soc Sci Med. 2005; 61(1):97-109.
30. Ng M, Fullman N, Dieleman JL, Flaxman AD, Murray CJ, Lim SS. Effective coverage: a metric for monitoring universal health coverage. PLoS Med. 2014; 11(9):e1001730.
31. Goldstein MC, Childs G, Wangdui P. Bei Jing’s "People First" development initiative for the Tibet Autonomous Region's rual sector-A case study from the ShiGaTse area. Chin J. 2010(63):57-75.
32. Charoendee K, Sriratanaban J, Aekplakorn W, Hanvoravongchai P. Assessment of population coverage of hypertension screening in Thailand based on the effective coverage framework. BMC Health Serv Res. 2018; 18(1):208.
33. Beaney T, Burrell LM, Castillo RR, Charchar FJ, Cro S, Damasceno A, et al. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. Eur Heart J. 2019; 40(25):2006-2017.
34. Baimakangzhuo, Chunhua, Yangla, et al. Alcohol drinking behavior among native adult Tibetans in Lhasa [in Chinese]. Chin J Public Health. 2015; 32(5):609-612.
35. Cochrane J, Chen H, Conigrave KM, Hao W. Alcohol use in China. Alcohol Alcohol 2003; 38(6):537-542.
36. Rehm J, Anderson P, Prieto JAA, Armstrong I, Aubin HJ, Bachmann M, et al. Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Med. 2017; 15(1):173.
37. Zhao Y, Yan H, Marshall RJ, Dang S, Yang R, Li Q. Trends in population blood pressure and prevalence, awareness, treatment, and control of hypertension among middle-aged and older adults in a rural area of Northwest China from 1982 to 2010. PloS One. 2013; 8(4):e61779.
38. Wilkins K, Campbell NR, Joffres MR, McAlister FA, Nichol M, Quach S, et al. Blood pressure in Canadian adults. Health Rep. 2010; 21(1):37.
39. Evans DB, Hsu J, Boerma T (eds.). Universal health coverage and universal access. Geneva, Switzerland: World Health Organization; 2013.
40. Zhang. D-W, Yang J-W, Cui J-L, LI X, Li J, Lu P-J. Regional differences in prevalence, awareness, treatment, and control of hypertension among five provinces in southwest China. Chin J Public Health[in Chinese]. 2019; 35(10):1293-1297.
41. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017; 390(10112):2549-2558.
42. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence and Control Among Adults: United States, 2015-2016. US Department of Health & Human Services. 2017(289):1-8.
43. Shafi ST, Shafi T. A survey of hypertension prevalence, awareness, treatment, and control in health screening camps of rural central Punjab, Pakistan. J Epidemiol Glob Health. 2017; 7(2):135-140.
44. Kayima J, Wanyenze RK, Katamba A, Leontsini E, Nuwaha F. Hypertension awareness, treatment and control in Africa: a systematic review. BMC Cardiovasc Disord. 2013; 13:54.
45. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008; 29(21):2669-2680.
46. Mufunda E, Albin B, Hjelm K. Differences in health and illness beliefs in zimbabwean men and women with diabetes. Open Nurs J. 2012; 6:117-125.
47. Lewis CL, Chrastil HJ, Schorr-Ratzlaff W, Lam H, McCord M, Williams L, et al. Achieving 70% Hypertension Control: How Hard Can It Be? Jt Comm J Qual Patient Saf. 2020 Jun; 46(6):335-341.
48. Aubrey-Bassler K, Fernandes C, Penney C, Cullen R, Meaney C, Sopcak N, et al. The effectiveness of a proven chronic disease prevention and screening intervention in diverse and remote primary care settings: an implementation study on the BETTER 2 Program. BJGP Open. 2019 Oct 29; 3(3):bjgpopen19X101656.